Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study
HIVEC with THP offered a satisfactory safety profile and similar effectiveness to BCG. Our findings suggest that it may be regarded as a viable supplementary treatment for high-risk NMIBC patients when there is a shortage of BCG.
Authors
- Eran Wu
- Zhilong Huang
- Weiming Liang
- Shibo Huang (ORCID: https://orcid.org/0009-0001-6811-2944)
- Xuedong Wei (ORCID: https://orcid.org/0000-0003-2000-2620)
- Qinghua He
Institutions
- Guangxi University of Science and Technology (CN)
Publication Details
- Journal
- BMC Urology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1186/s12894-025-01773-z
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Natural Science Foundation of Guangxi Province
- Guangxi University
- Guangxi University of Science and Technology